Siplizumab
Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]
References
- ↑ ClinicalTrials.gov
|
---|
| Intracellular (initiation) | |
---|
| Intracellular (reception) | |
---|
| Extracellular | |
---|
| |
---|
| Description |
- Physiology
- cells
- autoantigens
- autoantibodies
- complement
- surface antigens
- IG receptors
|
---|
| Disease |
- Allergies
- Immunodeficiency
- Immunoproliferative immunoglobulin disorders
- Hypersensitivity and autoimmune disorders
- Neoplasms and cancer
|
---|
| Treatment |
- Procedures
- Drugs
- antihistamines
- immunostimulants
- immunosuppressants
- monoclonal antibodies
|
---|
|
|
|
---|
| Immune system ("-l(i[m])-") | Human ("-limu-") | |
---|
| Mouse ("-limo-") | |
---|
| Chimeric ("-lixi-") | |
---|
| Humanized ("-lizu-") | |
---|
| Chimeric + humanized ("-lixizu-") | |
---|
|
---|
| Interleukin ("-k(i[n])-") | Human ("-kinu-") | |
---|
| Humanized ("-kizu-", "-kinzu-") | |
---|
|
---|
| Inflammatory lesions ("-les-") | |
---|
| |
---|
| Description |
- Physiology
- cells
- autoantigens
- autoantibodies
- complement
- surface antigens
- IG receptors
|
---|
| Disease |
- Allergies
- Immunodeficiency
- Immunoproliferative immunoglobulin disorders
- Hypersensitivity and autoimmune disorders
- Neoplasms and cancer
|
---|
| Treatment |
- Procedures
- Drugs
- antihistamines
- immunostimulants
- immunosuppressants
- monoclonal antibodies
|
---|
|
|